title: Human papillomavirus-related genital disease in the immunocompromised host: Part II.
abstract: Human papillomavirus is responsible for common condyloma acuminata and a number of premalignant and malignant anogenital lesions. The immunocompromised population is at particular risk because of a higher incidence of malignant transformation. Lesions in this population may prove refractory to standard treatment. This is part II of a two-part review that will discuss the treatment of condyloma acuminata and vaginal, vulvar, penile, and anal intraepithelial neoplasias. This article will provide an updated review of available treatments, with a focus on recent advances and the challenges faced in successfully treating human papillomavirus lesions in the immunocompromised host.
authors.affiliation: Department of Dermatology, Division of Infectious Diseases, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA.
authors.forename: Rachel H
authors.initials: RH
authors.lastname: Gormley
authors.forename: Carrie L
authors.initials: CL
authors.lastname: Kovarik
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use; D052685:Alphapapillomavirus; D000634:Aminoquinolines / Q000008:administration & dosage / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001005:Anus Neoplasms; D062688:Buschke-Lowenstein Tumor; D002392:Catechin / Q000031:analogs & derivatives / Q000627:therapeutic use; D002424:Caustics / Q000627:therapeutic use; D000077404:Cidofovir; D003218:Condylomata Acuminata / Q000628:therapy; D003376:Counseling; D017679:Cryotherapy; D003596:Cytosine / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D006801:Humans; D000077271:Imiquimod; D016867:Immunocompromised Host; D008297:Male; D009824:Ointments; D063065:Organophosphonates / Q000627:therapeutic use; D030361:Papillomavirus Infections / Q000188:drug therapy / Q000628:therapy*; D010412:Penile Neoplasms / Q000276:immunology / Q000628:therapy* / Q000821:virology; D011034:Podophyllotoxin / Q000627:therapeutic use; D011230:Precancerous Conditions; D016896:Treatment Outcome; D014238:Trichloroacetic Acid / Q000627:therapeutic use; D014625:Vaginal Neoplasms / Q000276:immunology / Q000628:therapy* / Q000821:virology; D014846:Vulvar Neoplasms / Q000276:immunology / Q000628:therapy* / Q000821:virology; D014860:Warts / Q000276:immunology / Q000628:therapy* / Q000821:virology
chemical_list: D000276:Adjuvants, Immunologic; D000634:Aminoquinolines; D000972:Antineoplastic Agents, Phytogenic; D000998:Antiviral Agents; D002424:Caustics; D009824:Ointments; D063065:Organophosphonates; D014238:Trichloroacetic Acid; D003596:Cytosine; D002392:Catechin; D000077404:Cidofovir; D011034:Podophyllotoxin; D000077271:Imiquimod; C472086:polyphenon E